Core Viewpoint - Heptagon Pharmaceuticals-B (02142) has seen a nearly 5% increase in stock price, currently at HKD 13.62, following the announcement of an expanded collaboration agreement with AstraZeneca PLC aimed at developing next-generation biotherapies, including antibody-drug conjugates (ADC) and T-cell connectors [1]. Company Summary - Heptagon Pharmaceuticals-B's stock price rose by 4.77% to HKD 13.62 with a trading volume of HKD 23.44 million [1]. - The company announced a collaboration, option, and licensing agreement with AstraZeneca PLC on November 24, 2023, which expands the scope of their partnership [1]. - The revised agreement aims to leverage the expertise of both companies to jointly discover and develop new biotherapies [1]. - The economic terms and financial framework established under the collaboration agreement remain consistent with previous agreements [1].
和铂医药-B早盘涨近5% 与阿斯利康进一步拓展合作范围